Compare iShares Gold Trust (IAU) vs Mesoblast Limited (MESO) Price & Performance

IAU, the iShares Gold Trust ETF, is trading at $83.305, up 0.96% with a bullish technical signal overall. The ETF benefits from gold's recent momentum as spot gold approaches $4,430/oz amid cooling inflation data and geopolitical tensions. Moving averages show bullish alignment while oscillators indicate some overbought conditions. Recent news highlights gold's safe-haven appeal with institutional buying and positive price forecasts.

The outlook remains positive given gold's role as an inflation hedge and safe-haven asset, supported by central bank demand and favorable CPI data. Risks include potential Fed policy shifts and dollar strength. Conservative investors favor IAU for its low 0.25% expense ratio and lower volatility compared to mining equities.

MESO trades at $16.9, up 1.32% on the day, with a bullish technical signal from moving averages. The company reported Ryoncil net revenues of $36 million for the quarter ended June 30, 2026, and achieved its target of 300 patients in a Phase 3 trial for chronic low back pain. Despite strong revenue growth from its commercial launch, fundamentals show a net income margin of -144.33% and negative EBITDA of $80.06 million for 2025, reflecting significant losses amid expansion.

The outlook hinges on commercial execution and regulatory progress, with analyst consensus leaning buy (45% buy ratings). Key risks include high cash burn, dependence on pipeline success, and competitive pressures. Upside potential exists if revenue growth accelerates and losses narrow, but investors face volatility from clinical trial outcomes and funding needs.